Compounds > diethoxyphosphoryloxymethyl butanoate
Page last updated: 2024-11-11

diethoxyphosphoryloxymethyl butanoate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

diethoxyphosphoryloxymethyl butanoate: butyroyloxymethyl-diethyl phosphate antitumor cpd; structure in first source; do not confuse with AN 7 peptide complex [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9837935
CHEMBL ID486366
SCHEMBL ID7781266
MeSH IDM0487562

Synonyms (9)

Synonym
butyroyloxymethyl-diethyl phosphate
butyroyloxymethyl diethylphosphate
diethoxyphosphoryloxymethyl butanoate
(diethoxyphosphoryloxy)methyl butyrate
CHEMBL486366
butanoic acid, [(diethoxyphosphinyl)oxy]methyl ester
213262-83-0
SCHEMBL7781266
DTXSID60431619
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID347407Increase in protoporphyrin 9 levels in human U251 cells at 200 uM after 24 hrs relative to control2008Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23
Novel multifunctional acyloxyalkyl ester prodrugs of 5-aminolevulinic acid display improved anticancer activity independent and dependent on photoactivation.
AID347392Cytotoxicity against human U251 cells after 72 hrs by Hoechst test2008Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23
Novel multifunctional acyloxyalkyl ester prodrugs of 5-aminolevulinic acid display improved anticancer activity independent and dependent on photoactivation.
AID347414Inhibition of 26S proteasome activity in human U251 cells at 100 uM after 24 hrs relative to control2008Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23
Novel multifunctional acyloxyalkyl ester prodrugs of 5-aminolevulinic acid display improved anticancer activity independent and dependent on photoactivation.
AID347399Increase in ROS production in human U251 cells at 50 uM after 4 hrs by FACS flow cytometry in presence of N-acetyl-L-cysteine2008Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23
Novel multifunctional acyloxyalkyl ester prodrugs of 5-aminolevulinic acid display improved anticancer activity independent and dependent on photoactivation.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's6 (50.00)29.6817
2010's5 (41.67)24.3611
2020's1 (8.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.87

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.87 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.87)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
aminolevulinic acid
Aminolevulinic Acid: A compound produced from succinyl-CoA and GLYCINE as an intermediate in heme synthesis. It is used as a PHOTOCHEMOTHERAPY for actinic KERATOSIS.. 5-aminolevulinic acid : The simplest delta-amino acid in which the hydrogens at the gamma position are replaced by an oxo group. It is metabolised to protoporphyrin IX, a photoactive compound which accumulates in the skin. Used (in the form of the hydrochloride salt)in combination with blue light illumination for the treatment of minimally to moderately thick actinic keratosis of the face or scalp.		2.04104-oxo monocarboxylic acid;
amino acid zwitterion;
delta-amino acid		antineoplastic agent;
dermatologic drug;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
photosensitizing agent;
plant metabolite;
prodrug;
Saccharomyces cerevisiae metabolite
butyric acid
Butyric Acid: A four carbon acid, CH3CH2CH2COOH, with an unpleasant odor that occurs in butter and animal fat as the glycerol ester.. butyrate : A short-chain fatty acid anion that is the conjugate base of butyric acid, obtained by deprotonation of the carboxy group.. butyric acid : A straight-chain saturated fatty acid that is butane in which one of the terminal methyl groups has been oxidised to a carboxy group.		2.7630fatty acid 4:0;
straight-chain saturated fatty acid		human urinary metabolite;
Mycoplasma genitalium metabolite
diethyl phosphate
diethyl phosphate: RN given refers to parent cpd. diethyl hydrogen phosphate : A dialkyl phosphate having ethyl as the alkyl group.		2.0710dialkyl phosphatehuman xenobiotic metabolite;
mouse metabolite
formaldehyde
paraform: polymerized formaldehyde; RN given refers to parent cpd; used in root canal therapy		2.0310aldehyde;
one-carbon compound		allergen;
carcinogenic agent;
disinfectant;
EC 3.5.1.4 (amidase) inhibitor;
environmental contaminant;
Escherichia coli metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
vorinostat
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.. vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).		2.1310dicarboxylic acid diamide;
hydroxamic acid		antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
pivalyloxymethyl butyrate
pivalyloxymethyl butyrate: structure given in first source		2.4420
ConditionIndicatedRelationship StrengthStudiesTrials
Cancer of Skin
[description not available]		02.1710
Cutaneous T-Cell Lymphoma
[description not available]		02.1710
Skin Neoplasms
Tumors or cancer of the SKIN.		02.1710
Lymphoma, T-Cell, Cutaneous
A group of lymphomas exhibiting clonal expansion of malignant T-lymphocytes arrested at varying stages of differentiation as well as malignant infiltration of the skin. MYCOSIS FUNGOIDES; SEZARY SYNDROME; LYMPHOMATOID PAPULOSIS; and PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA are the best characterized of these disorders.		02.1710
Erythroderma, Sezary
[description not available]		02.1310
Mycosis Fungoides
A chronic, malignant T-cell lymphoma of the skin. In the late stages, the LYMPH NODES and viscera are affected.		02.1310
Sezary Syndrome
A form of cutaneous T-cell lymphoma manifested by generalized exfoliative ERYTHRODERMA; PRURITUS; peripheral lymphadenopathy, and abnormal hyperchromatic mononuclear (cerebriform) cells in the skin, LYMPH NODES, and peripheral blood (Sezary cells).		02.1310
Metastase
[description not available]		02.7330
Neoplasm Metastasis
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.		02.7330
Benign Neoplasms, Brain
[description not available]		02.0710
Breast Cancer
[description not available]		02.4520
Astrocytoma, Grade IV
[description not available]		02.0710
Brain Neoplasms
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.		02.0710
Breast Neoplasms
Tumors or cancer of the human BREAST.		02.4520
Glioblastoma
A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.		02.0710
Anoxemia
[description not available]		02.0710
Cardiovascular Stroke
[description not available]		02.0710
Injury, Myocardial Reperfusion
[description not available]		02.0710
Hypoxia
Sub-optimal OXYGEN levels in the ambient air of living organisms.		02.0710
Myocardial Infarction
NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).		02.0710
Cancer of Lung
[description not available]		02.0710
Animal Mammary Carcinoma
[description not available]		02.0710
Lung Neoplasms
Tumors or cancer of the LUNG.		02.0710
Cancer of Prostate
[description not available]		02.4320
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		02.4320
Angiogenesis, Pathologic
[description not available]		02.0310